Key facts
- CytomX Therapeutics and Regeneron Pharmaceuticals have expanded a licensing agreement.
- Regeneron gains rights to develop and commercialize multiple drug candidates discovered by CytomX.
CytomX Therapeutics announced that it has entered into an expanded licensing agreement with Regeneron Pharmaceuticals. Under the terms of the agreement, Regeneron has been granted the rights to develop and commercialize multiple drug candidates that were discovered by CytomX. This expansion signifies a deepening collaboration between the two companies in the pharmaceutical development space.